Merck Emend Coverage Decision Will Not Affect Aloxi, MGI Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The Centers for Medicare & Medicaid Services' initiation of a national coverage determination process for Merck' anti-emetic Emend will have no impact on MGI Pharma's Aloxi, MGI CEO Lonnie Moulder said during a July 14 conference call